To assess the efficacy of four common regimes for thromboembolic prophylaxis after total knee arthroplasty (TKA): aspirin, warfarin, low molecular weight heparin (LMWH) and pneumatic compression.
assessment.

Data extraction
The authors do not state how the data were extracted for the review, or how many of the reviewers performed the data extraction.
Data were extracted for the categories of: study identification, type of study, the total number of patients, type of prophylaxis and the corresponding number of patients, and quality score. The authors of the primary studies were contacted for additional information where appropriate.
Methods of synthesis
How were the studies combined? Pooled odds ratios (ORs) with 95% confidence intervals (CIs) and p-values were calculated using the Mantel-Haenszel method.
How were differences between studies investigated?
The authors do not report any tests for assessing heterogeneity.
Results of the review
Twenty-three studies with 6,001 participants were included in the review.
The incidence of DVT was 53% (1,701 out of 3,214 participants) in the aspirin group, 45% (541 out of 1,203 participants) in the warfarin group, 29% (311 out of 1,075 participants) in the LMWH group, and 17% (86 out of 509 participants) in the pneumatic compression group.
Intermittent pneumatic compression devices were statistically significantly better than warfarin or aspirin in preventing DVT: the OR values were 1.9 (95% CI: 1.6, 2.3, p=0.003) and 3.2 (95% CI: 2.7, 3.8, p<0.0001), respectively.
LMWH was statistically significantly better than warfarin or aspirin in preventing DVT: the OR values were 2.05 (95% CI: 1.76, 2.39, p<0.0001) and 3.47 (95% CI: 3.04, 3.96, p<0.0001), respectively.
There was no significant difference between warfarin and aspirin (OR 1.7, 95% CI: 1.5, 1.9, p=0.4), or between LMWH and intermittent pneumatic compression (OR 1.09, 95% CI: 0.9, 1.33, p=0.4).
The incidence of asymptomatic PE was 11.7% in the aspirin group (222 out of 1,901 participants), 8.2% in the warfarin group (101 out of 1,229 participants), and 6.3% in the pneumatic compression group (24 out of 378 participants). No studies with LMWH used routine lung scans.
Pneumatic compression was statistically significantly better than aspirin and warfarin in preventing asymptomatic PE: the OR values were OR 2.5 (95% CI: 1.7, 3.8, p=0.0002) and 1.7 (95% CI: 1.1, 2.6, p=0.0003), respectively.
There was no significant difference between warfarin and aspirin (OR 1.2, 95% CI: not noted, p=0.5).
The incidence of symptomatic PE was 1.3% (23 out of 1,800 participants) in the aspirin group, 0.4% (2 out of 559 participants) in the warfarin group, 0.5% (2 out of 416 participants) in the LMWH group, and 0% (0 out of 177 participants) in the pneumatic compression group.
No statistically-significant differences between groups were noted for symptomatic PE: for warfarin compared with aspirin, the OR was 2.1 (95% CI 0.9, 4.8, p=1.0); for LMWH compared with aspirin and warfarin, the ORs were 2.7 (95% CI: 0.5, 14, p=0.9) and 1.8 (95% CI: 0.2, 14, p=0.2), respectively; and for pneumatic compression compared with aspirin, warfarin and LMWH, the ORs were 6.5 (95% CI: 0.4, 106, p=0.2), 3.0 (95% CI: 0.2, 53, p=0.6) and 2.4 (95% CI: 0.1, 59, p=0.03), respectively. 
